Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/ refractory indolent lymphoma

Blood

Volumn 125, Issue 21, 2015, Pages 3357-3359

  Cheah, Chan Yoon ^a   Nastoupil, Loretta J ^a   Neelapu, Sattva S ^a   Forbes, Sheryl G ^a   Oki, Yasuhiro ^a   Fowler, Nathan H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDELALISIB; LENALIDOMIDE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; URSODEOXYCHOLIC ACID; VORICONAZOLE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; THALIDOMIDE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLANGITIS; CHOLESTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLICULAR LYMPHOMA; FUNGUS ISOLATION; FUSARIOSIS; FUSARIUM; HUMAN; HUMAN TISSUE; IMMUNE DYSREGULATION; LETTER; LIVER BIOPSY; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG LAVAGE; LYMPHOCYTOMA; LYMPHOMA; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; SEPTIC SHOCK; SIDE EFFECT; THORAX PAIN; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PURINES; QUINAZOLINONES; RITUXIMAB; THALIDOMIDE;

EID: 84944960444     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-633156     Document Type: Letter

References (6)

1. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.
2. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
3. Zydelig (idelalisib) tablets, for oral use [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2015.
4. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1):22-32.
5. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J. 2012;442(3): 465-481.
6. Smith S, Pitcher BN, Jung SH, et al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202 [abstract]. Blood. 124(21). Abstract 3091.